Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Preserving Our Hometown Independent Pharmacies Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1188)
Preserving Our Hometown Independent Pharmacies Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1188)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2014 · third_quarter · 3A
Regulatory implementation of various tax provisions in the health reform legislation
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1188)
Source: Senate LDA
Preserving Our Hometown Independent Pharmacies Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1188)
Preserving Our Hometown Independent Pharmacies Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1188)
Preserving Our Hometown Independent Pharmacies Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1188)
FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit design and pricing (MAC)issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding. S. 867, the Medicare Prescription Drug Program Integrity and Transparency Act.
FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit design and pricing (MAC)issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding. S. 867, the Medicare Prescription Drug Program Integrity and Transparency Act.
Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare regulatory/legislative proposals to impede audit, mail order and preferred network restrictions.S. 867, Medicare Prescription Drug Integrity and And Transparency Act of 2013. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc). Issues regarding Maximum Allowable Cost (HR 4437)
Generic Drug Pricing Fairness Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare regulatory/legislative proposals to impede audit, mail order and preferred network restrictions.S. 867, Medicare Prescription Drug Integrity and And Transparency Act of 2013. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc). Issues regarding Maximum Allowable Cost (HR 4437)
Generic Drug Pricing Fairness Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Generic Drug Pricing Fairness Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Generic Drug Pricing Fairness Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Generic Drug Pricing Fairness Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Generic Drug Pricing Fairness Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Generic Drug Pricing Fairness Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Generic Drug Pricing Fairness Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Generic Drug Pricing Fairness Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Ensuring Seniors Access to Local Pharmacies Act of 2014
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Ensuring Seniors Access to Local Pharmacies Act of 2014
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Ensuring Seniors Access to Local Pharmacies Act of 2014
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Ensuring Seniors Access to Local Pharmacies Act of 2014
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Ensuring Seniors Access to Local Pharmacies Act of 2014
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Ensuring Seniors Access to Local Pharmacies Act of 2014
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Ensuring Seniors Access to Local Pharmacies Act of 2014
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Ensuring Seniors Access to Local Pharmacies Act of 2014
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Patients' Access to Treatments Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Patients' Access to Treatments Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Patients' Access to Treatments Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures Issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). Restrictions on specialty tiering; HR 460
Patients' Access to Treatments Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Patients' Access to Treatments Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures Issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). Restrictions on specialty tiering; HR 460
Patients' Access to Treatments Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures Issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). Restrictions on specialty tiering; HR 460
Patients' Access to Treatments Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures Issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). Restrictions on specialty tiering; HR 460
Patients' Access to Treatments Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Medicare Prescription Drug Program Integrity and Transparency Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Medicare Prescription Drug Program Integrity and Transparency Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Medicare Prescription Drug Program Integrity and Transparency Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Medicare Prescription Drug Program Integrity and Transparency Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Medicare Prescription Drug Program Integrity and Transparency Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Medicare Prescription Drug Program Integrity and Transparency Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Medicare Prescription Drug Program Integrity and Transparency Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare regulatory/legislative proposals to impede audit, mail order and preferred network restrictions.S. 867, Medicare Prescription Drug Integrity and And Transparency Act of 2013. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc). Issues regarding Maximum Allowable Cost (HR 4437)
Medicare Prescription Drug Program Integrity and Transparency Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Medicare Prescription Drug Program Integrity and Transparency Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit design and pricing (MAC)issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding. S. 867, the Medicare Prescription Drug Program Integrity and Transparency Act.
Medicare Prescription Drug Program Integrity and Transparency Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Preserving Our Hometown Independent Pharmacies Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1188)
Preserving Our Hometown Independent Pharmacies Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1188)
Preserving Our Hometown Independent Pharmacies Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1188)
Preserving Our Hometown Independent Pharmacies Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1188)
FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding. S. 867, the Medicare Prescription Drug Program Integrity and Transparency Act.
FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding. S. 867, the Medicare Prescription Drug Program Integrity and Transparency Act.
FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding. S. 867, the Medicare Prescription Drug Program Integrity and Transparency Act.
FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse. General issues dealing with pharmacy drug compounding.
Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding. S. 867, the Medicare Prescription Drug Program Integrity and Transparency Act.
Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Medicare Prescription Drug Program Integrity and Transparency Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding. S. 867, the Medicare Prescription Drug Program Integrity and Transparency Act.
Medicare Prescription Drug Program Integrity and Transparency Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013. General issues regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Medicare Prescription Drug Program Integrity and Transparency Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding. S. 867, the Medicare Prescription Drug Program Integrity and Transparency Act.
Medicare Prescription Drug Program Integrity and Transparency Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding. S. 867, the Medicare Prescription Drug Program Integrity and Transparency Act.
Medicare Prescription Drug Program Integrity and Transparency Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013. General issues regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Medicare Prescription Drug Program Integrity and Transparency Act of 2013
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Quality Health Care Coalition Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839). Advocacy surrounding proposed corporate merger.
Quality Health Care Coalition Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
Quality Health Care Coalition Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
Quality Health Care Coalition Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
Community Pharmacy Fairness Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
Community Pharmacy Fairness Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
Community Pharmacy Fairness Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839). Advocacy surrounding proposed corporate merger.
Community Pharmacy Fairness Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
Preserving Our Hometown Independent Pharmacies Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
Preserving Our Hometown Independent Pharmacies Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
Preserving Our Hometown Independent Pharmacies Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
Preserving Our Hometown Independent Pharmacies Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839). Advocacy surrounding proposed corporate merger.
Pharmacy Competition and Consumer Choice Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse. General issues dealing with pharmacy drug compounding.
Pharmacy Competition and Consumer Choice Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058).
Pharmacy Competition and Consumer Choice Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse
Pharmacy Competition and Consumer Choice Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Medicare Drug Savings Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Medicare Drug Savings Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Medicare Drug Savings Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Medicare Drug Savings Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Medicare Prescription Drug Price Negotiation Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Medicare Prescription Drug Price Negotiation Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Medicare Prescription Drug Price Negotiation Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Medicare Prescription Drug Price Negotiation Act of 2011
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Postal Reform proposals and their impact on 6 day mail delivery: S 1789 and HR 2309
Postal Reform proposals and their impact on 6 day mail delivery: S 1789 and HR 2309
Generic Drug and Biosimilar User Fee Act of 2012
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse. General issues dealing with pharmacy drug compounding.
Generic Drug and Biosimilar User Fee Act of 2012
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse
Generic Drug and Biosimilar User Fee Act of 2012
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Pharmacy issues related to Section 700 (Champus provisions) of the annual defense bill
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures Issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). Restrictions on specialty tiering; HR 460
Postal Reform proposals and their impact on 6 day mail delivery
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2014 · third_quarter · Q3
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1188)
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures Issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). Restrictions on specialty tiering; HR 460
Postal Reform proposals and their impact on 6 day mail delivery
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Pharmacy issues related to Section 700 (Champus provisions) of the annual defense bill
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Regulatory implementation of various tax provisions in the health reform legislation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2014 · second_quarter · 2A
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Pharmacy issues related to Section 700 (Champus provisions) of the annual defense bill
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Postal Reform proposals and their impact on 6 day mail delivery
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1188)
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures Issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). Restrictions on specialty tiering; HR 460
Regulatory implementation of various tax provisions in the health reform legislation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2014 · second_quarter · Q2
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Pharmacy issues related to Section 700 (Champus provisions) of the annual defense bill
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures Issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). Restrictions on specialty tiering; HR 460
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Postal Reform proposals and their impact on 6 day mail delivery
Regulatory implementation of various tax provisions in the health reform legislation
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1188)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2014 · first_quarter · Q1
Pharmacy issues related to Section 700 (Champus provisions) of the annual defense bill
Regulatory implementation of various tax provisions in the health reform legislation
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1188)
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare regulatory/legislative proposals to impede audit, mail order and preferred network restrictions.S. 867, Medicare Prescription Drug Integrity and And Transparency Act of 2013. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc). Issues regarding Maximum Allowable Cost (HR 4437)
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures Issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit design and pricing (MAC)issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding. S. 867, the Medicare Prescription Drug Program Integrity and Transparency Act.
Postal Reform proposals and their impact on 6 day mail delivery
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2013 · fourth_quarter · Q4
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1188)
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2013 · third_quarter · Q3
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013. General issues regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures Issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2013 · second_quarter · Q2
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures Issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Pharmacy issues related to Section 700 (Champus provisions) of the annual defense bill
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013. General issues regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2013 · first_quarter · Q1
Pharmacy issues related to Section 700 (Champus provisions) of the annual defense bill
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions.
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse. General issues dealing with pharmacy drug compounding.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2012 · fourth_quarter · Q4
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse. General issues dealing with pharmacy drug compounding.
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2012 · third_quarter · Q3
Postal Reform proposals and their impact on 6 day mail delivery: S 1789 and HR 2309
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2012 · second_quarter · Q2
Pharmacy issues related to Section 700 (Champus provisions) of the annual National Defense Authorization Act of 2012.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2012 · first_quarter · Q1
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839). Advocacy surrounding proposed corporate merger.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2011 · fourth_quarter · 4A
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839). Advocacy surring proposed corporate merger.
HR 4, Comprehensive 1099 Taxpayer Protection and Repayment of Exchange Subsidy Overpayments Act of 2011 Regulatory implementation of various tax provisions in the health reform legislation Repeal of the 3% tax withholding requirement for federal contractors.
Trans Pacific Partnership trade agreements impact on biosimilar drug market exclusivity length.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2011 · fourth_quarter · Q4
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058).
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs)
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2011 · third_quarter · Q3
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs)
HR 4, Comprehensive 1099 Taxpayer Protection and Repayment of Exchange Subsidy Overpayments Act of 2011 Regulatory implementation of various tax provisions in the health reform legislation Repeal of the 3% tax withholding requirement for federal contractors
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058).
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2011 · second_quarter · Q2
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General regulatory changes and legislative issues that impact the Part D program such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733).
Issues related to Section 700 (Champus provisions) of the annual National Defense Authorization Act of 2012
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2011 · first_quarter · Q1
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH FDA issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs)
HR 1409, Legislation to exempt health care providers (including pharmacies) from the antitrust laws for purposes of negotiating with payers.
Issues related to Section 700 (Champus provisions) of the annual National Defense Authorization Act for 2012
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2010 · fourth_quarter · Q4
Exclusion of specialty distributors' prompt pay discounts from the definition of averages sales price Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap, drug copay waivers. Reform proposals that impact Medicaid such as statutory changes to average manufacture price. General regulatory changes to the Medicare Part D program.
HR. 1204--Pharmacies Antitrust Carve-out Legislation
Regulatory policies related to health reform, structure, PBM and drug benefits--HR 3590, HR 4872 Establishment of a regulatory pathway for biogenerics/biosimilars--HR 3590 Regulatory implementation issues of HITECH (ARRA, HR 1)
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2010 · third_quarter · Q3
Exclusion of specialty distributors' prompt pay discounts from the definition of average sales price Health reform proposals that impact Medicare Part D such as formulary requirements, waiver of anti-kickback statutes for generic drug copay waivers, direct negotiation, Medicaid rebate changes, PBM disclosure provisions, closing the Part D coverage gap--HR 3590 and HR 4872 (PPACA/Health care reform)
H.R. 806, Mail Order Demonstration program for TRICARE Items related to implementing federal ceiling prices for prescription drugs dispensed at retail within the TRICARE program. H.R. 5013, the IMPROVE Acquisition Act HR 5136/S 3280, National Defense Authorization Act of 2011 (Section 700 CHAMPUS issues)
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2010 · second_quarter · Q2
H.R. 806, Mail Order Demonstration program for TRICARE Items related to implementing federal ceiling prices for prescription drugs dispensed at retail within the TRICARE program. H.R. 5013, the IMPROVE Acquisition Act HR 5136/S 3280, National Defense Authorization Act of 2011 (Section 700 CHAMPUS issues)
Items related to reverse settlement payments between manufacturers--HR 1706, S 369 Policies related to the Federal Employees Health Benefit program's pharmacy benefit program--HR 4489 Design and coverage of pharmacy benefits in health reform legislation as well as PBM disclosure requirements--HR 3590, HR 4872 Policies related to restricting PBMs' ability to manage prescription drug benefits -- HR 4199 HR 5234, PBM Audit Reform and Transparency Act
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2010 · first_quarter · Q1
Items related to reverse settlement payments between manufacturers--HR 1706, S 369 Policies related to the Federal Employees Health Benefit program's pharmacy benefit program--HR 4489 Design and coverage of pharmacy benefits in health reform legislation as well as PBM disclosure requirements--HR 3590, HR 4872 Policies related to restricting PBMs' ability to manage prescription drug benefits -- HR 4199
H.R. 806, Mail Order Demonstration program for TRICARE Items related to implementing federal ceiling prices for prescription drugs dispensed at retail within the TRICARE program. H.R. 5013, the IMPROVE Acquisition Act
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2009 · fourth_quarter · Q4
Establishment of a regulatory pathway for biogenerics/biosimilars--S. 1679, HR 1427, HR 1548, S. 726, HR 3962, HR 3950 Items related to the regulatory implementation of HITECH, HR 1 Items relating to health care reform bills, structure, pharmacy benefit managers transparency requirements--HR 3962, Affordable Health Care for America Act; HR 3950, Patient Protection and Affordable Care Act
Items related to reverse settlement payments between manufacturers--HR 1706, S. 369, HR 3590; HR 3962 Items related to oversight of the federal employees health benefits program and its pharmacy benefit Design and coverage of pharmacy benefits in new Health Exchanges/Gateways as well as pharmacy benefit managers transparency requirements--HR 3962, Affordable Health Care for America Act; HR 3950, Patient Protection and Affordable Care Act HR 4199, PHARMACY bill, items related to restricting PBMs ability to manage prescription drug benefits.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2009 · third_quarter · Q3
Exclusion of specialty distributors' prompt pay discounts from the definition of average sales price, HR 1392, HR 3200 Various regulatory items related to Medicare Part B, Part D and workers' compensation Health reform proposals that would impact Part D such as formulary requirements, relaxation of anti-kickback statutes for generic drug copay waivers, direct negotiation, Medicaid rebate changes--America's Healthy Future Act, S. 1679, HR 3200
H.R. 1204--Pharmacists Antitrust carve out legislation
H.R. 806--mail order demonstration program for TRICARE Items related to implementing federal ceiling prices for prescription drugs dispensed at retail within the TRICARE program.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2009 · second_quarter · Q2
Items related to reverse settlement payments between manufacturers, HR 1706 Changing the definition of first-to-file between manufacturers, S 1315 Items related to oversight of the federal employees health benefit program and its pharmacy benefit
Exclusion of specialty distributors' prompt pay discounts from the definition of average sales price, HR 1392 Various regulatory items related to Medicare Part B, Part D and workers compensation Expansion of Medicaid pricing rebates, S 330, Hr 904, S 547 Various health reform proposals that would impact Part D and Medicare Advantage
H.R. 806--mail order demonstration program for TRICARE Items related to implementing federal ceiling prices for prescription drugs dispensed at retail within the TRICARE program.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2009 · first_quarter · Q1
Items related to reverse settlement payments between manufacturers, H.R. 1706
H.R. 1204, Pharmacists' Antitrust carve out; H.R. 1409/S. 560, Employee Free Choice Act
Exclusion of specialty distributors' prompt payment discounts from the definition of average sales price, H.R. 1392 Various regulatory items related to the Medicare Part D benefits Expansion of Medicaid pricing, S. 330, HR. 904, S. 547
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2008 · fourth_quarter · Q4
Genetic Information Nondiscrimination Act (HR 493/S 358) Issues relating to promoting health information technology/EMR/privacy (HR 3800/S 1693/HR 6898/HR 6357)
Issues relating to the DOL's propsoed disclosure of compensation for service fee providers under ERISA Providing an antitrust exemption for independent pharmacies HR 800 /S 1041 -- issues relating to amending the NLRA bargaining and organizing
HR 1038/HR 1956/HR5629--creation of a regulatory pathway for generic biologics S 1088/S 28/S 316/HR 1902--issues related to bringing generics to market in a timely fashion S. 596/S 980/HR 6353--internet pharmacy regulations HR 5839--issues relating to prescription drug pedigree/drug safety
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2008 · third_quarter · Q3
Issues relating to the DOL's proposed disclosure of compensation for service fee providers under ERISA Providing an antitrust exemption for independent pharmacies (HR 971/S 885/S 2161)
HR 1038/HR 1956/S 1695/HR 5629--creation of a regulatory pathway for generic biologics S 1088/S 28/S 316/HR 1902--Issues related to bringing generics to market in a timely fashion S. 596/S. 980/HR 6353--internet pharmacy regulations HR 5839--issues relating to prescription drug pedigree/drug safety
Medicare Part D: prompt pay/EFT for pharmacies (HR 1474/S 1827/S 1954/HR 6331), Changes to the part D benefit (HR 3162/S 2499/HR 6331), Electronic prescribing and eRx for controlled substances (HR 4296/S 2408/HR 6331), access to Medicare Data (HR 6388/S 1507/HR 6331), various regulatory issues related to Part D benefit. Medicare Part B: Changes to the competitive acquisition program for biologics (HR 3162) and prompt pay exclusion for distribution (HR 2770); AMP changes (HR 6331)
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2008 · second_quarter · Q2
Items relating to the implementation of PL 110-85, the FDA reauthorization Act of 2007 HR 1038/HR 1956/S. 1695/HR 5629--regulatory pathway for generic biologics S. 1088/S. 28/S. 316/HR 1902--Issues related to bringing generics to market in a timely fashion S. 596/S. 980--internet pharmacy regulations Issues relating to the DOL's proposed disclosure of compensation for service fee providers under ERISA
Issues related to fully funding the pharmacy benefit under the military health care system--2009 Defense Authorization and Appropriations bills. Items related to the structure of the pharmacy benefit of the MHS and the implementation of federal pricing for prescription drugs at retail pharmacy.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2008 · first_quarter · Q1
Providing an antitrust exemption for independent pharmacies--HR 971/S 885/ S. 2161
Items related to the implementation of PL 110-85, the FDA reauthorization act of 2007 HR 1038/HR 1956/S 1695/ HR 5629--Regulatory pathway for generic biologics S 1088/S 28/S 316/HR 1902--Issues related to bring generics to market in a timely fashion S 596/S 980 -- Internet pharmacies Issues relating to the DOL's proposed disclosure of compensation for service fee providers under ERISA
Medicare Part D: Prompt pay/EFT for pharmacies (HR 1474/S 1827); changes to the Part D benefit (HR 3162/S 2499); direct negotiation (HR 4/S 1); electronic prescribing (S2408/HR 4296; various regulatory issues related to implementing the Medicare Part D drug benefit. Medicare Part B: Changes to the competitive acquisition program (HR 3162); prompt pay exclusion from Part B (HR 2770) Issues related to the definition of Average Manufacture Price (AMP) as espoused by the Deficit Reduction Act of 2005.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2007 · year_end · YY
Medicare Part D: Prompt pay/EFT for pharmacies (HR 1474, S 1827); changes to the Part D benefit (HR 3162/S. 2499)); direct negotiation (HR 4/ S 1); electronic prescribing (S2408/HR 4296); various regulatory issues related to implementing the Medicare Part D drug benefit Medicare Part B: Changes to the competitive acquisition program (HR 3162); prompt pay exclusion from ASP (HR 2770)
S 1082/HR 2900--FDA reauthorization (follow on biologics, citizens petition reform, pediatric exclusivity reform, pedigree) S. 623/HR 1038/HR 1956/S. 1695--Regulatory pathway for generic biologics S 1088/S 25/S 28/S 316/ HR 1902--Issues relating to bringing generics to market in a timely fashion S 1376/HR 2606--expansion of 340b pricing
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2007 · mid_year · MA
Providing an antitrust exemption for pharmacies--HR 971/ S 885
S 1082/HR 2900--FDA reauthorization (follow on biologics, citizens petition reform, pediatric exclusivity reform, pedigree) S. 623/HR 1038/HR 1956--Regulatory pathway for generic biologics S 1088/S 25/S 28/S 316/ HR 1902--Issues relating to bringing generics to market in a timely fashion S 1376/HR 2606--expansion of 340b pricing
Items related to fully funding the pharmacy benefit under the military health system--2008 Defense Authorization bills (HR 1585/S 1547. Promoting TRICARE's mail order program--HR 2319 Items relating to the structure of the pharmacy benefit of the military health system
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2007 · mid_year · MM
Issues relating to the definition of Average Manufacture Price (AMP) as espoused by the Deficit Reduction Act Issues related to Medicare Part B and Part D: S. 870/HR 2567 to provide coverage of home infusion services and supplies under Medicare. Medicare Part D: Prompt pay/EFT for pharmacies (HR 1474, S 1827); changes to the Part D benefit (HR 3162/HR 976 (senate bill)); direct negotiation (HR 4/ S 1); electronic prescribing; various regulatory issues related to implementing the Medicare Part D drug benefit Medicare Part B: Changes to the competitive acquisition program (HR 3162); prompt pay exclusion from ASP (HR 2770)
S 1082/HR 2900--FDA reauthorization (follow on biologics, citizens petition reform, pediatric exclusivity reform, pedigree) S. 623/HR 1038/HR 1956--Regulatory pathway for generic biologics S 1088/S 25/S 28/S 316/ HR 1902--Issues relating to bringing generics to market in a timely fashion S 1376/HR 2606--expansion of 340b pricing
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2006 · year_end · YY
NDAA of 2007, HR5122/S2507, fully funding the defense health program
Implementation of the Deficit Reduction Act of 2006 (AMP/Medicaid subrogation) Items related to MMA 2003 (Part D and B/ASP+6%) Pharmacy Prompt pay/MTM--HR 2563/HR 2551/S2665/HR5182
Issues related to pharmacists being able to collectively bargain/HR 1669; Regulation of PBMs/HR 5384; Fully funding the FDA's OGD/HR 5384; Closing Rx patent loop-holes/S2300; generic biologics HR 6257
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2006 · mid_year · MM
-Wired for Health Care Act, S. 1418 -Health Information Technology Promotion Act, HR 4157 -Bioterrorism Preparedness, S. 1873, S. 2564, S. 3678 -Issues relating to HHS' regulations on Stark/Fraud and Abuse for Health IT
-Items related to implementation of Deficit Reduction Act, PL 109-171, AMP and Medicaid subrogation -Items related to the implementation of the Medicare Moderization Act, including ASP+6% & the Competitive Acquisition Program; Part D -Prompt pay and MTM legislation - HR 5166, S. 2563, S. 2551, HR 5182 -Payment support for home infusion therapy
-Items related to fulling funding the defense health program and preserving mail order options -NDAA of 2007 - HR 5122, S. 2507
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2005 · year_end · YY
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Economic Development Administration, HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE, White House Office
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2005 · mid_year · MM
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2005 · mid_year · RR
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures Issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Postal Reform proposals and their impact on 6 day mail delivery
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding. S. 867, the Medicare Prescription Drug Program Integrity and Transparency Act.
Pharmacy issues related to Section 700 (Champus provisions) of the annual defense bill
Regulatory implementation of various tax provisions in the health reform legislation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
Pharmacy issues related to Section 700 (Champus provisions) of the annual defense bill
Postal Reform proposals and their impact on 6 day mail delivery
Regulatory implementation of various tax provisions in the health reform legislation
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding. S. 867, the Medicare Prescription Drug Program Integrity and Transparency Act.
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1188)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding. S. 867, the Medicare Prescription Drug Program Integrity and Transparency Act.
Postal Reform proposals and their impact on 6 day mail delivery (continuing resolution)
Regulatory implementation of various tax provisions in the health reform legislation
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1188)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1188)
Regulatory implementation of various tax provisions in the health reform legislation
Postal Reform proposals and their impact on 6 day mail delivery (continuing resolution)
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures Issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, White House Office
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Medicare audit restrictions (HR 4215)
Postal Reform proposals and their impact on 6 day mail delivery: S 1789 and HR 2309
Regulatory implementation of various tax provisions in the health reform legislation
Pharmacy issues related to Section 700 (Champus provisions) of the annual National Defense Authorization Act of 2012--specifically promotion of House TMOP demonstration program
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, White House Office
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
Pharmacy issues related to Section 700 (Champus provisions) of the annual National Defense Authorization Act of 2012--specifically promotion of House TMOP demonstration program
Regulatory implementation of various tax provisions in the health reform legislation
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, White House Office
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act: S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516: issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).
Regulatory implementation of various tax provisions in the health reform legislation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, White House Office
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs)
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058).
Pharmacy issues related to Section 700 (Champus provisions) of the annual National Defense Authorization Act of 2012.
Trans Pacific Partnership trade agreements impact on biosimilar drug market exclusivity length.
HR 4, Comprehensive 1099 Taxpayer Protection and Repayment of Exchange Subsidy Overpayments Act of 2011 Regulatory implementation of various tax provisions in the health reform legislation Repeal of the 3% tax withholding requirement for federal contractors.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, U.S. Trade Representative (USTR), White House Office
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs)
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Policy considerations of the Jt. Comm on Deficit Reduct
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058).
Pharmacy issues related to Section 700 (Champus provisions) of the annual National Defense Authorization Act of 2012.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, U.S. Trade Representative (USTR), White House Office
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839). Advocacy surring proposed corporate merger.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Policy considerations of the Jt. Comm on Deficit Reduct
Pharmacy issues related to Section 700 (Champus provisions) of the annual National Defense Authorization Act of 2012.
Trans Pacific Partnership trade agreements impact on biosimilar drug market exclusivity length.
HR 4, Comprehensive 1099 Taxpayer Protection and Repayment of Exchange Subsidy Overpayments Act of 2011 Regulatory implementation of various tax provisions in the health reform legislation Repeal of the 3% tax withholding requirement for federal contractors.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, U.S. Trade Representative (USTR), White House Office
Issues related to Section 700 (Champus provisions) of the annual National Defense Authorization Act of 2012
Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839). Advocacy surrounding proposed corporate merger.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Policy considerations of the Jt. Comm on Deficit Reduc.
Trans Pacific Partnership trade agreements impact on biosimilar drugs market exclusivity length.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, U.S. Trade Representative (USTR), White House Office
Legislation to exempt certain pharmacies from the antitrust laws for puposes of negotiating with payers (HR 1409, HR 1946, HR 1839)
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (essential health benefits, grandfathering, value-base insurance design, Rx quality, electronic prescribing, PBM disclosure requirements, medical loss ratio); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; Implementation of Zadroga Health Care Act; Legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058)
Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs)
HR 4, Comprehensive 1099 Taxpayer Protection and Repayment of Exchange Subsidy Overpayments Act of 2011 Regulatory implementation of various tax provisions in the health reform legislation Repeal of the 3% tax withholding requirement for federal contractors
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Executive Office of the President (EOP), Federal Trade Commission (FTC), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, White House Office
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General regulatory changes and legislative issues that impact the Part D program such as EGWP waivers and MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of Average Manufacture Price in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733).
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (essential health benefits, grandfathering, value-base insurance design, Rx quality, electronic prescribing, PBM disclosure requirements, medical loss ratio); legislation to promote generic drugs; regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; Zadroga implement.
HR 4, Comprehensive 1099 Taxpayer Protection and Repayment of Exchange Subsidy Overpayments Act of 2011 Regulatory implementation of various tax provisions in the health reform legislation Repeal of the 3% tax withholding requirement for federal contractors
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Executive Office of the President (EOP), Federal Trade Commission (FTC), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, White House Office
H.R. 806, Mail Order Demonstration program for TRICARE Items related to implementing federal ceiling prices for prescription drugs dispensed at retail within the TRICARE program. H.R. 5013, the IMPROVE Acquisition Act HR 5136/S 3280, National Defense Authorization Act of 2011 (Section 700 CHAMPUS issues)
Items related to reverse settlement payments between manufacturers--HR 1706, S 369; Policies related to the Federal Employees Health Benefit program's pharmacy benefit program--HR 4489; Regulatory design and coverage of pharmacy benefits in health reform legislation as well as PBM disclosure requirements; Policies related to restricting PBMS' ability to manage prescription drug benefits-- HR 4199; PBM Audit Reform & Transparency Act--HR 5234.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Items related to reverse settlement payments between manufacturers--HR 1706, S 369 Policies related to the Federal Employees Health Benefit program's pharmacy benefit program--HR 4489 Design and coverage of pharmacy benefits in health reform legislation as well as PBM disclosure requirements--HR 3590, HR 4872 Policies related to restricting PBMs' ability to manage prescription drug benefits -- HR 4199 HR 5234, PBM Audit Reform and Transparency Act
Policies related to health reform, structure, PBM and drug benefit requirements--HR 3590, HR 4872 Establishment of a regulatory pathway for biogenerics/biosimilars--HR 3590 Regulatory implementation issues of HITECH, (ARRA, HR 1)
H.R. 1204--Pharmacies Antitrust carve out legislation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, White House Office
H.R. 1204--Pharmacies Antitrust carve out legislation
Policies related to health reform, structure, PBM and drug benefit requirements--HR 3590, HR 4872 Establishment of a regulatory pathway for biogenerics/biosimilars--HR 3590 Regulatory implementation issues of HITECH, (ARRA, HR 1)
Exclusion of specialty distributors' prompt pay discounts from the definition of average sales price Health reform proposals that impact Medicare Part D such as formulary requirements, waiver of anti-kickback statutes for generic drug copay waivers, direct negotiation, Medicaid rebate changes, PBM disclosure provisions, closing the Part D coverage gap--HR 3590 and HR 4872 (PPACA/Health care reform)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, White House Office
H.R. 1204--Pharmacies Antitrust carve out legislation
Exclusion of specialty distributors' prompt pay discounts from the definition of average sales price Health reform proposals that impact Medicare Part D such as formulary requirements, waiver of anti-kickback statutes for generic drug copay waivers, direct negotiation, Medicaid rebate changes, PBM disclosure provisions, closing the Part D coverage gap--HR 3950 and HR 4872 (PPRACA)
Policies related to health reform, structure, PBM and drug benefit requirements--HR 3590, HR 4872 Establishment of a regulatory pathway for biogenerics/biosimilars--HR 3590 Regulatory implementation issues of HITECH, (ARRA, HR 1)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Exclusion of specialty distributors' prompt pay discounts from the definition of average sales price, HR 1392, HR 3200 Various regulatory items related to Medicare Part B, Part D and workers' compensation Health reform proposals that would impact Part D such as formulary requirements, waiver of anti-kickback statutes for generic drug copay waivers, direct negotiation, Medicaid rebate changes, PBM disclosure provisions, closing Medicare Part D's coverage gap-- HR 3962, Affordable Health Care for America Act HR 3950, Patient Protection and Affordable Care Act
H.R. 806 Mail Order Demostration program for TRICARE Items related to implementing federal ceiling prices for prescription drugs dispensed at retail within the TRICARE program. H.R.3326, Making appropriations for the Department of Defense for the fiscal year ending September 30, 2010
H.R. 1204 -- Pharmacies Antitrust carve out legislation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE, White House Office
Establishment of a regulatory pathway for biogenerics/biosimilars--HR 3200, S. 1679, HR 1427, HR 1548, S. 726 Items related to the regulatory implementation of HITECH, HR 1 Items relating to health care reform bills, structure, pharmacy benefit managers transparency requirements--America's Healthy Future Act, HR 3200, S. 1679
Items related to reverse settlement payments between manufacturers--HR 1706, S. 369 Items related to oversight of the federal employees health benefits program and its pharmacy benefit Design and coverage of pharmacy benefits in new Health Exchanges/Gateways as well as pharmacy benefit managers transparency requirements--America's Healthy Future Act, S. 1679, HR 3200
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
Establishment of a regulatory pathway for biogenerics, HR 1427, HR 1548, S 726 Physician Sunshine Act, S. 301 Health information technology & changes to the HIPAA privacy laws, H.R. 1 General items relating to health care reform bills, structure, public plan: Affordable Health Care Choices & TriCommittee bill
H.R. 1204, Pharmacists Antitrust carve out
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
H.R. 806--Mail order demonstration program for TRICARE; Items related to implementing federal ceiling prices to prescription drugs dispensed at retail within the TRICARE program
Establishment of a regulatory pathway for biogenerics, H.R. 1427, H.R. 1548, S. 726 Physician Sunshine Act, S. 301 Health information technoglogy & changes to the HIPAA privacy law, H.R. 1
Filing targets: Congressional Budget Office (CBO), Defense, Dept of (DOD), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
Regulatory and Legislative items related to the structure and support of full funding of the military health care system. Regulatory implementation of federal pricing for prescription drugs at retail pharmacy.
Medicare Part D: prompt pay/EFT for pharmacies (HR 6331/MIPAA), changes to Part D benefit (HR 3162/HR 6331), Electronic prescribing & eRx for controlled substances (HR 63331, agency), access to Medicare Data (HR 6331/MIPAA), various regulatory issues related to Part D benefit. Medicare Part B: changes to the competitive acquisition program for biologics (regulatory) and prompt pay exclusion for specialty distributors (HR 2770), AMP changes (HR 6331 & MIPAA)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Legal Services Corporation, Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
Genetic Information Nondiscrimination Act (HR 493/S 358), Health Information technolgoy (HR 3800/S 1693/HR 6898/HR 6357)
Items related to the structure of the pharmacy benefit of the military health system. Implementation of federal pricing for prescription drugs at retail pharmacy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
Medicare Part D: prompt pay/EFT for pharmacies (HR 1474/S 1827/ S 1954/HR 6331), changes to the Part D benefit (HR 3162/S 2499/HR 6331), electronic prescribing (H.R. 4296/S 2408/ HR 6331), Access to Medicare Data (H.R. 6388/S 1507), various regulatory issues related to implementing the Medicare Part D benefit. Medicare Part B: Changes to the competitive acquisition program (HR 3162); prompt pay exculsion from Part B (HR 2770) Items related to the definition of Medicaid Average Manufacture Price (AMP) as espoused by the 2005 Deficit Reduction Act. (HR 3700/HR 6331)
Genetic Information Nondiscrimination Act (HR 493/S 358), Health information technology (HR 3800/S 1693)
providing an antitrust exemption for independent pharmacies (HR 971/S. 885/S 2161)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), SENATE, White House Office
Items related to fully funding the pharmacy benefit under the military health care system--2009 Defense Authorization bills Items related to the structure of the pharmacy benefit of the MHS and the implementation of federal pricing for prescription drugs at retail pharmacy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), SENATE, White House Office
Providing an antitrust exemption for pharmacies--HR 971/ S 885/ S. 2161
Items related to fully funding the pharmacy benefit under the military health system--2008 Defense Authorization bills (HR 1585/S 1547/ HR 2986). Promoting TRICARE's mail order program--HR 2319 Items relating to the structure of the pharmacy benefit of the MHS and the implementation of federal pricing at retail.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, White House Office
Issues relating to the definition of Average Manufacture Price (AMP) as espoused by the Deficit Reduction Act Issues related to Medicare Part B and Part D: S. 870/HR 2567 to provide coverage of home infusion services and supplies under Medicare. Medicare Part D: Prompt pay/EFT for pharmacies (HR 1474, S 1827); changes to the Part D benefit (HR 3162/HR 976 (senate bill)); direct negotiation (HR 4/ S 1); electronic prescribing; various regulatory issues related to implementing the Medicare Part D drug benefit Medicare Part B: Changes to the competitive acquisition program (HR 3162); prompt pay exclusion from ASP (HR 2770)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, White House Office
Providing an antitrust exemption for pharmacies--HR 971/ S 885
Items related to fully funding the pharmacy benefit under the military health system--2008 Defense Authorization bills (HR 1585/S 1547. Promoting TRICARE's mail order program--HR 2319
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, White House Office
generic biologics/HR6257; Health IT/HR 4157/S1418; Bioterrorism Preparedness/S1873/S2564 (patent exculsivity provisions)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
-Issues relating to pharmacists being able to collectively bargain-HR 1671 -Regulation of pharmacy benefit managers-HR 1669 -Fully funding the FDA's Office of Generic Drugs - HR 5384 -Lower Priced Drug Act, S. 2300
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE